Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Anne B. Stewart"'
Autor:
Laura Price, Ruth R. Wexler, Patrick Y.S. Lam, Pancras C. Wong, Dietmar A. Seiffert, Ming Chang, Joanna Zheng, Earl J. Crain, Robert P. Rehfuss, Carol A. Watson, Tammy C. Wang, Gerry Everlof, William A. Schumacher, Christine Huang, Charles G. Clark, Qimin Wu, Anne B. Stewart, Jeffrey S. Bostwick, Jennifer X. Qiao, Ji Jua
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 23:3239-3243
Preclinical data suggests that P2Y1 antagonists, such as diarylurea compound 1, may provide antithrombotic efficacy similar to P2Y12 antagonists and may have the potential of providing reduced bleeding liabilities. This manuscript describes a series
Autor:
Michael A. Poss, Ming Chang, Dora M. Schnur, Timothy F. Herpin, Ruth R. Wexler, Jacques Y. Roberge, Maredith Arcuri, Robert P. Rehfuss, Deborah Celani, Yalei Liu, Huji Turdi, Angela Cacace, Christine Huang, William A. Schumacher, Martin L. Ogletree, Hannguang Chao, Qimin Wu, Anne B. Stewart, Ji Hua, R. Michael Lawrence, Jeffrey S. Bostwick, Thomas E. Steinbacher, Laura Price, Lynn M. Abell
Publikováno v:
Journal of Medicinal Chemistry. 56:1704-1714
Two distinct G protein-coupled purinergic receptors, P2Y1 and P2Y12, mediate ADP-driven platelet activation. The clinical effectiveness of P2Y12 blockade is well established. Recent preclinical data suggest that P2Y1 and P2Y12 inhibition provide equi
Autor:
Eddie C.-K. Liu, Martin L. Ogletree, William A. Schumacher, Steven E. Seiler, Anne B. Stewart, Jeffrey S. Bostwick, Karen S. Hartl, Thomas E. Steinbacher
Publikováno v:
European Journal of Pharmacology. 570:167-174
The effect of inhibiting activated blood coagulation factor XIa was determined in rat models of thrombosis and hemostasis. BMS-262084 is an irreversible and selective small molecule inhibitor of factor XIa with an IC(50) of 2.8 nM against human facto
Autor:
Jergen Baumann, William A. Schumacher, Thomas E. Steinbacher, Jean H.M. Feyen, Joseph Tamasi, Yizhi Liu, Eileen Bird, James K. Tamura, Anne B. Stewart, Jeffrey S. Bostwick
Publikováno v:
Thrombosis Research. 120:549-558
Introduction TAFI indirectly reduces the action of tPA on plasminogen. Whether exogenous tPA is necessary for TAFI inhibitor efficacy is unclear. Potato carboxypeptidase inhibitor (PCI), a TAFI inhibitor, has shown variable tPA dependence in rat mode
Autor:
Robert P. Rehfuss, Paul Levesque, Juliang Zhu, Arvind Mathur, Dietmar A. Seiffert, Bang-Chi Chen, Rejean Ruel, Laura Price, Yufeng Wang, Mary F. Malley, Xue-Qing Chen, Wu Yang, Ji Hua, Tammy C. Wang, William A. Schumacher, Yajun Liu, Dauh-Rurng Wu, Silvi A. Chacko, Jeffrey S. Bostwick, Charles G. Clark, Danshi Li, Patrick Y.S. Lam, Henry S. Wong, Anne B. Stewart, Dawn Sun, Ruth R. Wexler, Hong Shen, Sheldon Hiebert, Christine Huang, Ling Li, Jeon Yoon T, Carl Thibeault, Jennifer X. Qiao
Publikováno v:
Bioorganicmedicinal chemistry letters. 24(5)
Spiropiperidine indoline-substituted diaryl ureas had been identified as antagonists of the P2Y1 receptor. Enhancements in potency were realized through the introduction of a 7-hydroxyl substitution on the spiropiperidinylindoline chemotype. SAR stud
Autor:
Pancras C. Wong, Thomas E. Steinbacher, Anne B. Stewart, Jeffrey S. Bostwick, William A. Schumacher, Baomin Xin
Publikováno v:
Journal of cardiovascular pharmacology. 55(6)
Apixaban is an oral, direct, and highly selective factor Xa inhibitor in late-stage clinical development for the prevention and treatment of thromboembolic diseases. Apixaban was evaluated in rat thrombosis and hemostasis models. Thrombosis was produ
Autor:
William A. Schumacher, Pancras C. Wong, Laura Price, Ji Hua, Thomas E. Steinbacher, Jeffrey S. Bostwick, Anne B. Stewart, Martin L. Ogletree, Robert P. Rehfuss
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 322(1)
We determined the dose response of the ADP antagonist clopidogrel (0.3-50 mg/kg p.o.) in rat models of thrombosis and provoked bleeding and correlated these activities to ex vivo platelet activation. Carotid artery thrombosis was induced by FeCl(2).
Autor:
William A. Schumacher, Pancras C. Wong, Jeffrey S. Bostwick, Anne B. Stewart, Thomas E. Steinbacher, Donald J. P. Pinto
Publikováno v:
Blood. 110:4005-4005
Apixaban is an oral, direct and highly selective factor Xa inhibitor which is in late stage clinical development for the prevention and treatment of thromboembolic diseases. Apixaban is potent against human and rat factor Xa (Ki = 0.08 and 1.3 nM, re